Iron deficiency in renal disease plays a substantial role as a very common cause. So, it is important to regularly monitor iron profile in hemodialysis chronic kidney disease (CKD) patients who receives iron treatment to ensure that iron overload and its toxic remarks do not occur.
Materials and Method: 60 patients with ESRD and 60 normal, healthy subjects as control were included in the study. The parameters considered was HB level, serum iron, TIBC, unsaturated iron-binding capacity (UIBC), serum ferritin, TSAT, C-reactive protein (CRP), blood urea, and serum creatinine. The patients (stage V) who were on parenteral iron therapy for a period of a minimum of 3 months were included in the study.
Results: 120 adults were studied; 60 patients with ESRD and 60 healthy controls. 81%) were male and 19%) were female among the patients, with a mean age of 51.4 ± 13.2 years. For controls, 83% were male 17% were female with a mean age of 32.0 ± 13.5 years. The findings of the present study shows that the HB level of the patients under dialysis was significantly lower as compared to the controls as well as the serum TIBC.
Conclusion: With the help of our study we can conclude that the average percentage of TSAT and serum ferritin level indicates increased iron availability in ESRD patients which, may cause acquired hemochromatosis. CRP elevation was pronounced and could explain the inflammatory activity status. Estimation of CRP marker is a superior simple test in predicting the outcome of hemodialysis patients.